306 related articles for article (PubMed ID: 31990338)
1. Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry.
Vadillo C; Nieto MA; Romero-Bueno F; Leon L; Sanchez-Pernaute O; Rodriguez-Nieto MJ; Freites D; Jover JA; Álvarez-Sala JL; Abasolo L
Rheumatology (Oxford); 2020 Aug; 59(8):2099-2108. PubMed ID: 31990338
[TBL] [Abstract][Full Text] [Related]
2. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.
Md Yusof MY; Kabia A; Darby M; Lettieri G; Beirne P; Vital EM; Dass S; Emery P
Rheumatology (Oxford); 2017 Aug; 56(8):1348-1357. PubMed ID: 28444364
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in connective tissue disease-associated interstitial lung disease.
Duarte AC; Cordeiro A; Fernandes BM; Bernardes M; Martins P; Cordeiro I; Santiago T; Seixas MI; Ribeiro AR; Santos MJ
Clin Rheumatol; 2019 Jul; 38(7):2001-2009. PubMed ID: 31016581
[TBL] [Abstract][Full Text] [Related]
4. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
[TBL] [Abstract][Full Text] [Related]
5. Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease.
Narváez J; Robles-Pérez A; Molina-Molina M; Vicens-Zygmunt V; Luburich P; Yañez MA; Alegre JJ; Nolla JM
Semin Arthritis Rheum; 2020 Oct; 50(5):902-910. PubMed ID: 32906025
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease.
Li L; Liu R; Zhang Y; Zhou J; Li Y; Xu Y; Gao S; Zheng Y
Clin Rheumatol; 2020 May; 39(5):1457-1470. PubMed ID: 31858341
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
Chartrand S; Swigris JJ; Peykova L; Fischer A
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):296-304. PubMed ID: 26847096
[TBL] [Abstract][Full Text] [Related]
8. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
Curtis JR; Sarsour K; Napalkov P; Costa LA; Schulman KL
Arthritis Res Ther; 2015 Nov; 17():319. PubMed ID: 26555431
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: Clinical features, biomarkers, and treatment options.
Chen N; Diao CY; Gao J; Zhao DB
Semin Arthritis Rheum; 2022 Aug; 55():152004. PubMed ID: 35472663
[TBL] [Abstract][Full Text] [Related]
10. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.
Rojas-Serrano J; Herrera-Bringas D; Pérez-Román DI; Pérez-Dorame R; Mateos-Toledo H; Mejía M
Clin Rheumatol; 2017 Jul; 36(7):1493-1500. PubMed ID: 28585060
[TBL] [Abstract][Full Text] [Related]
11. Comment on: Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry.
Satış H; Oruç A; Avcu A; Karadeniz H; Güler AA; Kayahan N
Rheumatology (Oxford); 2020 Aug; 59(8):2180. PubMed ID: 32442283
[No Abstract] [Full Text] [Related]
12. Comment on: Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry: reply.
Vadillo C; Nieto MA; Romero-Bueno F; Leon L; Sanchez-Pernaute O; Rodriguez-Nieto MJ; Freites D; Jover LJA; Álvarez-Sala JL; Abasolo L
Rheumatology (Oxford); 2020 Aug; 59(8):2181-2182. PubMed ID: 32447385
[No Abstract] [Full Text] [Related]
13. Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study.
Sparks JA; He X; Huang J; Fletcher EA; Zaccardelli A; Friedlander HM; Gill RR; Hatabu H; Nishino M; Murphy DJ; Iannaccone CK; Mahmoud TG; Frits ML; Lu B; Rosas IO; Dellaripa PF; Weinblatt ME; Karlson EW; Shadick NA; Doyle TJ
Arthritis Rheumatol; 2019 Sep; 71(9):1472-1482. PubMed ID: 30951251
[TBL] [Abstract][Full Text] [Related]
14. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.
Fernández-Díaz C; Castañeda S; Melero-González RB; Ortiz-Sanjuán F; Juan-Mas A; Carrasco-Cubero C; Casafont-Solé I; Olivé A; Rodríguez-Muguruza S; Almodóvar-González R; Castellanos-Moreira R; Rodríguez-García SC; Aguilera-Cros C; Villa I; Ordóñez-Palau S; Raya-Alvarez E; Morales-Garrido P; Ojeda-García C; Moreno-Ramos MJ; Bonilla Hernán MG; Hernández Rodríguez I; López-Corbeto M; Andreu JL; Jiménez de Aberásturi JRD; Ruibal-Escribano A; Expósito-Molinero R; Pérez-Sandoval T; López-Robles AM; Carreira-Delgado P; Mena-Vázquez N; Urruticoechea-Arana A; Peralta-Ginés C; Arboleya-Rodríguez L; Narváez García FJ; Palma-Sánchez D; Cervantes Pérez EC; Maiz-Alonso O; Alvarez-Rivas MN; Fernández-Melón J; Vela Casasempere P; Cabezas-Rodríguez I; Castellvi-Barranco I; González-Montagut C; Blanco-Madrigal J; Del Val-Del Amo N; Fito MC; Rodríguez-Gómez M; Salgado-Pérez E; García-Magallón B; Hidalgo-Calleja C; López-Sánchez R; Fernández-Aguado S; Fernández-López JC; Castro-Oreiro S; Serrano-García I; García-Valle A; Romero-Yuste S; Expósito-Pérez L; Pérez-Albadalejo L; García-Aparicio A; Quillis-Marti N; Bernal-Vidal JA; Loricera-García J; Hernández JL; González-Gay MA; Blanco R
Rheumatology (Oxford); 2020 Dec; 59(12):3906-3916. PubMed ID: 33068439
[TBL] [Abstract][Full Text] [Related]
15. Mortality rate in rheumatoid arthritis-related interstitial lung disease: the role of radiographic patterns.
Nieto MA; Rodriguez-Nieto MJ; Sanchez-Pernaute O; Romero-Bueno F; Leon L; Vadillo C; Freites-Nuñez DD; Jover JA; Álvarez-Sala JL; Abasolo L
BMC Pulm Med; 2021 Jun; 21(1):205. PubMed ID: 34193085
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
Baker MC; Liu Y; Lu R; Lin J; Melehani J; Robinson WH
JAMA Netw Open; 2023 Mar; 6(3):e233640. PubMed ID: 36939701
[TBL] [Abstract][Full Text] [Related]
17. High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease.
Tyker A; Ventura IB; Lee CT; Strykowski R; Garcia N; Guzy R; Jablonski R; Vij R; Strek ME; Chung JH; Adegunsoye A
Sci Rep; 2021 Nov; 11(1):22821. PubMed ID: 34819525
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.
Matson SM; Baqir M; Moua T; Marll M; Kent J; Iannazzo NS; Boente RD; Donatelli JM; Dai J; Diaz FJ; Demoruelle MK; Hamblin MB; Mathai SK; Ryu JH; Pope K; Walker CM; Lee JS
Chest; 2023 Apr; 163(4):861-869. PubMed ID: 36470416
[TBL] [Abstract][Full Text] [Related]
19. Rheumatoid arthritis related interstitial lung disease - improving outcomes over 25 years: a large multicentre UK study.
Kelly CA; Nisar M; Arthanari S; Carty S; Woodhead FA; Price-Forbes A; Middleton D; Dempsey O; Miller D; Basu N; Dawson J; Sathi N; Ahmad Y; Palmer E; Iqbal K; Janakiraman G; Koduri G; Young A
Rheumatology (Oxford); 2021 Apr; 60(4):1882-1890. PubMed ID: 33150434
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population.
Fu Q; Wang L; Li L; Li Y; Liu R; Zheng Y
Clin Rheumatol; 2019 Apr; 38(4):1109-1116. PubMed ID: 30535993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
